Guohui H. Cui
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: December 23, 2025
Analysis and reflections on the current status of diagnosis and treatment of marginal zone lymphoma
Journal: Zhonghua yi xue za zhi
Published: December 18, 2024
Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2.
Journal: Frontiers in immunology
Published: November 11, 2024
Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Journal: Cancer biology & therapy
Published: October 31, 2023
Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial.
Journal: Chinese medical journal
Published: July 27, 2023
Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.
Journal: Clinical and experimental medicine
Published: July 24, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study.
Journal: Innovation (Cambridge (Mass.))
Published: January 04, 2023
Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma.
Journal: Cancer medicine
Published: September 20, 2022
Secondary Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus-Associated Transformed Follicular Lymphoma: A Case Report and Literature Review.
Journal: Frontiers in oncology
Published: March 16, 2021
The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.
Journal: Translational oncology
Published: December 08, 2020
Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Journal: Cancer communications (London, England)
Published: September 07, 2020
Last Updated: 09/26/2026